Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. Kelley RK, et al. J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22. J Clin Oncol. 2021. PMID: 34292792 Free PMC article. Clinical Trial.
"And what other medications are you taking?".
Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. Gordan JD, et al. Among authors: kelley rk. J Clin Oncol. 2011 Apr 10;29(11):e288-91. doi: 10.1200/JCO.2010.32.8054. Epub 2011 Jan 18. J Clin Oncol. 2011. PMID: 21245436 No abstract available.
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Ko AH, et al. Among authors: kelley rk. Am J Clin Oncol. 2012 Oct;35(5):411-7. doi: 10.1097/COC.0b013e3182185888. Am J Clin Oncol. 2012. PMID: 21552099 Clinical Trial.
Multidisciplinary management of hepatocellular carcinoma.
Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Guy J, et al. Among authors: kelley rk. Clin Gastroenterol Hepatol. 2012 Apr;10(4):354-62. doi: 10.1016/j.cgh.2011.11.008. Epub 2011 Nov 12. Clin Gastroenterol Hepatol. 2012. PMID: 22083023 Review.
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB 3rd, Venook AP. Kelley RK, et al. Ann Oncol. 2013 Jul;24(7):1900-1907. doi: 10.1093/annonc/mdt109. Epub 2013 Mar 21. Ann Oncol. 2013. PMID: 23519998 Free PMC article. Clinical Trial.
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. Bendell JC, et al. Among authors: kelley rk. Cancer. 2015 Oct 1;121(19):3481-90. doi: 10.1002/cncr.29422. Epub 2015 Jul 15. Cancer. 2015. PMID: 26177599 Free PMC article. Clinical Trial.
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL. Papadopoulos KP, et al. Among authors: kelley rk. Clin Cancer Res. 2016 Mar 15;22(6):1348-55. doi: 10.1158/1078-0432.CCR-15-1221. Epub 2015 Oct 21. Clin Cancer Res. 2016. PMID: 26490310 Clinical Trial.
185 results